Study details
Enrolling now
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT IDNCT07303894ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 6 years
Ages
18+
Locations
8 sites in MA, NJ, NY
About this study
This trial is testing whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Isoquercetin
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Oncology